ライフサイエンスコーパス: varicella zoster

1 prophylaxis against Pneumocystis carinii and varicella zoster.

2 and pneumonia, and an increase observed for varicella zoster.

3 -mg dose of fingolimod: disseminated primary varicella zoster and herpes simplex encephalitis.

4 varicella-zoster virus vaccine in preventing varicella-zoster and herpes zoster is well documented, a

5 smosis, other infections (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus,

6 reaction (PCR) analysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus an

7 ependent promoter and a model activator, the varicella zoster IE62 protein, it was determined that HC

8 Prophylaxis with varicella-zoster immunoglobulin can reduce the severity

9 number and critical immunization coverage of varicella-zoster infection in Belgium, Italy, Poland, an

10 y cells is presumably the initiating step of varicella-zoster infection.

11 virus (OPV), rubella, measles, yellow fever, varicella-zoster, multivalent measles/mumps/rubella, and

12 of herpes zoster disease, which is caused by Varicella zoster Nevertheless, the pathophysiological me

13 Only a few varicella-zoster nucleocapsids and cytoplasmic virions w

14 roidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoi

15 clonal expansions in response to attenuated varicella-zoster vaccination in four pairs of adult iden

16 laria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III).

17 Two doses of live-attenuated varicella-zoster vaccine are recommended for human immun

18 thy, such as prior herpes simplex keratitis, varicella-zoster viral keratitis, the linear form of Thy

19 e calculated an anterograde velocity for the varicella zoster virion of 5.55 mm/h or .0015 mm/s.

20 = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

21 s HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytome

22 tients showed a decreased ability to control varicella zoster virus (VZV) and Epstein-Barr virus (EBV

23 Varicella zoster virus (VZV) and the two herpes simplex

24 Varicella zoster virus (VZV) antibody titers (measured b

25 Varicella zoster virus (VZV) antigen was found in all of

26 Vasculopathies caused by varicella zoster virus (VZV) are indicative of a product

27 CMV and varicella zoster virus (VZV) are significant causes of m

28 response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzym

29 lex virus types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain

30 se of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a

31 , or no history of zoster (group 3) revealed varicella zoster virus (VZV) DNA in saliva samples from

32 rs who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs of skin inocul

33 Herpesvirions and varicella zoster virus (VZV) DNA were recently reported

34 Varicella zoster virus (VZV) establishes latency in dors

35 Varicella zoster virus (VZV) establishes lifelong persis

36 as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and further char

37 s positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of

38 Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovere

39 Reactivation of the varicella zoster virus (VZV) increases during aging.

40 Varicella zoster virus (VZV) infections are a relevant c

41 virus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored i

42 Varicella zoster virus (VZV) is a neurotropic alphaherpe

43 Varicella Zoster Virus (VZV) is the causative agent of v

44 Varicella zoster virus (VZV) is the etiological agent of

45 Varicella zoster virus (VZV) reactivation results in zos

46 An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being de

47 zoster (HZ) cases may play a larger role in varicella zoster virus (VZV) transmission.

48 Varicella zoster virus (VZV) typically causes chickenpox

49 ne responses to a high-titer live attenuated varicella zoster virus (VZV) vaccine (zoster vaccine), w

50 Since the introduction of live attenuated varicella zoster virus (VZV) vaccine in 1995 there has b

51 s, granulomatous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

52 portion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed the positive pred

53 c primers to detect DNA from JC virus (JCV), varicella zoster virus (VZV), cytomegalovirus (CMV), Eps

54 on childhood disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

55 erpesviruses, herpes simplex virus (HSV) and varicella zoster virus (VZV), results in the rapid accum

56 immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereaft

57 Boost of varicella zoster virus (VZV)-specific cellular immunity

58 We investigated the relationship between varicella zoster virus (VZV)-specific memory CD4(+) T ce

59 virus type 1 (HSV-1) and type 2 (HSV-2) and varicella zoster virus (VZV)-was determined in autonomic

60 ses with age, which leads to reactivation of varicella zoster virus (VZV).

61 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV).

62 For herpes simplex virus, varicella zoster virus and cytomegalovirus, these advanc

63 RN, PCR-positive for herpes simplex virus or varicella zoster virus and evaluated between January 200

64 genes of both herpes simplex virus (HSV) and varicella zoster virus and functions, in part, by coupli

65 beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

66 ld decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of

67 (as determined by testing lesions swabs for varicella zoster virus DNA by polymerase chain reaction)

68 ence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from

69 Varicella zoster virus DNA was detected 2 months after t

70 Varicella zoster virus encodes an immediate-early (IE) p

71 were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy

72 rveillance, combined with information from a Varicella Zoster Virus Identification Program, which use

73 cation) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95

74 contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, a

75 processes, including ubiquitin clearance and Varicella Zoster Virus infection.

76 nd increased susceptibility to bacterial and varicella zoster virus infections.

77 Similarly, in a varicella zoster virus lytic infection, HCF-1, Set1, and

78 One patient with varicella zoster virus meningitis and acute GVHD had iC9

79 e fills a notable gap in our knowledge about varicella zoster virus neuronal transportation.

80 Because there is no good animal model of varicella zoster virus reactivation from latency, this e

81 -Barr virus, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex

82 ty of herpes simplex virus, cytomegalovirus, varicella zoster virus, and Epstein-Barr virus in our po

83 Herpes simplex virus, varicella zoster virus, and pseudorabies virus are neuro

84 nstrate that childhood infections, including varicella zoster virus, are associated with an increased

85 for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections)

86 itis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of

87 se encephalitis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus an

88 deficiency virus (HIV)-herpes simplex virus, varicella zoster virus, Epstein-Barr virus (EBV), and cy

89 gnificant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epste

90 genes, Treponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and He

91 highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinica

92 ese is also activated by the closely related varicella zoster virus.

93 ew mutations or recombination with wild-type Varicella zoster virus.

94 2, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus.

95 1), P. jirovecii pneumonia (1.77; .42-7.47), varicella-zoster virus (1.51; .71-3.22), as well as over

96 Varicella-zoster virus (VZV) activates the phosphatidyli

97 SV functioned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjace

98 are the main architectural contrasts between varicella-zoster virus (VZV) and herpes simplex virus (H

99 d the Us9 homologs from two human pathogens, varicella-zoster virus (VZV) and herpes simplex virus ty

100 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infe

101 Although the homologs from varicella-zoster virus (VZV) and human cytomegalovirus (

102 simplex virus type 1 (HSV-1) is conserved in varicella-zoster virus (VZV) and pseudorabies virus (PRV

103 ype 1 (EHV-1), pseudorabies virus (PRV), and varicella-zoster virus (VZV) and their subsequent functi

104 Simian varicella virus (SVV) and varicella-zoster virus (VZV) are closely related alphahe

105 gument proteins encoded by ORF11 and ORF9 of varicella-zoster virus (VZV) are conserved among all alp

106 mmunity and protects against reactivation of varicella-zoster virus (VZV) as HZ.

107 Infection of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of in

108 y, IDE has been proposed as the receptor for varicella-zoster virus (VZV) attachment.

109 The attenuation of varicella-zoster virus (VZV) by Takahashi in 1974 was a

110 Serum was tested for antibodies against varicella-zoster virus (VZV) by use of the previously va

111 Varicella-zoster virus (VZV) causes chicken pox and shin

112 Varicella-zoster virus (VZV) causes chickenpox and react

113 highly infectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shing

114 ating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shing

115 Varicella-zoster virus (VZV) causes chickenpox upon prim

116 Varicella-zoster virus (VZV) causes varicella and establ

117 Varicella-zoster virus (VZV) causes varicella, establish

118 Varicella-zoster virus (VZV) characteristically forms mu

119 y throughout the study and were analyzed for varicella-zoster virus (VZV) DNA by use of both qualitat

120 Wild-type varicella-zoster virus (VZV) DNA was identified in all 3

121 15, pain was scored and saliva examined for varicella-zoster virus (VZV) DNA.

122 Herein we describe an episode of focal varicella-zoster virus (VZV) encephalitis in a healthy y

123 Varicella-zoster virus (VZV) establishes a lifelong late

124 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong late

125 Varicella-zoster virus (VZV) establishes latency in huma

126 ts had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measu

127 When grown in cultured cells, varicella-zoster virus (VZV) forms many aberrant light p

128 Information about varicella-zoster virus (VZV) gB is limited, but homology

129 Varicella-zoster virus (VZV) glycoprotein E (gE) is esse

130 Varicella-zoster virus (VZV) glycoprotein E (gE) is requ

131 tive target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of pe

132 Mechanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to st

133 umoral and cell-mediated immune responses to varicella-zoster virus (VZV) have been evaluated after 1

134 (EBV) EB2, herpes simplex virus (HSV) ICP27, varicella-zoster virus (VZV) IE4/ORF4, and cytomegalovir

135 The varicella-zoster virus (VZV) IE62 protein is the major t

136 Varicella-zoster virus (VZV) immediate-early 63 protein

137 ction by enveloped, but not cell-associated, varicella-zoster virus (VZV) in a dose-dependent manner

138 ects immediate-early protein IE63 encoded by varicella-zoster virus (VZV) in the cytoplasm of product

139 Varicella-zoster virus (VZV) induces apoptosis in human

140 Previous studies have demonstrated that varicella-zoster virus (VZV) infection activates ERK1/2,

141 Varicella-zoster virus (VZV) infection causes varicella,

142 Primary varicella-zoster virus (VZV) infection in humans produce

143 Varicella-zoster virus (VZV) infection is usually mild i

144 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human

145 acaques (RMs) recapitulates the hallmarks of varicella-zoster virus (VZV) infection of humans, includ

146 Varicella-zoster virus (VZV) infection provides a valuab

147 he lytic, latent, and reactivating phases of varicella-zoster virus (VZV) infection were recapitulate

148 extensively studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observe

149 Varicella-zoster virus (VZV) infections increasingly are

150 Varicella-zoster virus (VZV) is a common pathogen that c

151 Varicella-zoster virus (VZV) is a highly contagious agen

152 Varicella-zoster virus (VZV) is a highly neurotropic vir

153 Varicella-zoster virus (VZV) is a human alpha-herpesviru

154 Varicella-zoster virus (VZV) is a human alphaherpesvirus

155 Varicella-zoster virus (VZV) is a human alphaherpesvirus

156 Varicella-zoster virus (VZV) is a human neurotropic alph

157 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-acti

158 Varicella-zoster virus (VZV) is a member of the Herpesvi

159 Varicella-zoster virus (VZV) is a neurotropic alphaherpe

160 Varicella-zoster virus (VZV) is a ubiquitous pathogen th

161 Varicella-zoster virus (VZV) is a ubiquitous, highly cel

162 Varicella-zoster virus (VZV) is an alphaherpesvirus that

163 Varicella-zoster virus (VZV) is an alphaherpesvirus that

164 Varicella-zoster virus (VZV) is an alphaherpesvirus that

165 Varicella-zoster virus (VZV) is an extremely cell-associ

166 Varicella-zoster virus (VZV) is highly cell associated w

167 mary infection, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

168 Varicella-zoster virus (VZV) is renowned for its low tit

169 Varicella-zoster virus (VZV) is renowned for its very lo

170 Varicella-zoster virus (VZV) is the alphaherpesvirus tha

171 Varicella-zoster virus (VZV) is the causative agent of b

172 Varicella-zoster virus (VZV) is the causative agent of c

173 Varicella-zoster virus (VZV) is the etiological agent of

174 The varicella-zoster virus (VZV) major transactivator, IE62,

175 We report a case of AIDS presenting as varicella-zoster virus (VZV) meningomyeloradiculitis ass

176 To efficiently generate varicella-zoster virus (VZV) mutants, we inserted a bact

177 f herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneou

178 Varicella-zoster virus (VZV) open reading frame (ORF) 63

179 Varicella-zoster virus (VZV) open reading frame (ORF) 63

180 Varicella-zoster virus (VZV) open reading frame 10 (ORF1

181 Based on comparative genome analyses, varicella-zoster virus (VZV) open reading frame 23 (ORF2

182 The varicella-zoster virus (VZV) open reading frame 54 (ORF5

183 Varicella-zoster virus (VZV) open reading frame 61 (ORF6

184 Three loci in varicella-zoster virus (VZV) open reading frame 62 (ORF6

185 Varicella-zoster virus (VZV) open reading frame 63 (ORF6

186 Varicella-zoster virus (VZV) open reading frame 66 (ORF6

187 The gene cluster composed of varicella-zoster virus (VZV) open reading frame 9 (ORF9)

188 f transcripts corresponding to all 68 unique varicella-zoster virus (VZV) open reading frames (ORFs)

189 The varicella-zoster virus (VZV) ORF61 protein is necessary

190 The architecture of the varicella-zoster virus (VZV) origin of DNA replication (

191 The varicella-zoster virus (VZV) origin of DNA replication (

192 In this report, we show that ORF61p, the varicella-zoster virus (VZV) ortholog of ICP0, does not

193 ced syncytium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and senso

194 this minireview is to provide an overview of varicella-zoster virus (VZV) phylogenetics and phylogeog

195 We examined varicella-zoster virus (VZV) polymerase chain reaction (

196 er acyclovir prophylaxis should be given for varicella-zoster virus (VZV) prophylaxis after hematopoi

197 Analyses of varicella-zoster virus (VZV) protein expression during l

198 ORF66p, a virion-associated varicella-zoster virus (VZV) protein, is a member of a c

199 nt is associated with increased incidence of varicella-zoster virus (VZV) reactivation in patients wi

200 IMPORTANCE The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly ma

201 a total of five major genotypes among the 22 varicella-zoster virus (VZV) strains or isolates for whi

202 Varicella-zoster virus (VZV) T-cell responses by interfe

203 Varicella-zoster virus (VZV) T-cell-mediated immunity (V

204 The varicella-zoster virus (VZV) terminase components (pORF2

205 r herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by usi

206 Studies of varicella-zoster virus (VZV) tropism for T cells support

207 Although a varicella-zoster virus (VZV) vaccine has been used for m

208 75 years) immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

209 of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine.

210 Varicella-zoster virus (VZV) vasculopathy produces strok

211 ish adverse events associated with wild-type varicella-zoster virus (VZV) versus those associated wit

212 Varicella-zoster virus (VZV), a double-stranded DNA alph

213 igated during the entire infectious cycle of varicella-zoster virus (VZV), a human herpesvirus.

214 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activa

215 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesv

216 Regulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotr

217 1) and pseudorabies virus (PRV) and ORF66 in varicella-zoster virus (VZV), affects several viral and

218 Varicella-zoster virus (VZV), an alphaherpesvirus restri

219 Here we report that varicella-zoster virus (VZV), an alphaherpesvirus that i

220 pear healthy at 2 weeks after infection with varicella-zoster virus (VZV), and the cell culture mediu

221 ovirus, herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).

222 sviruses, herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), confirmed the expression o

223 ults for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or

224 In this study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HS

225 Levels of inhibition of varicella-zoster virus (VZV), human cytomegalovirus (HCM

226 Varicella-zoster virus (VZV), in both wild-type and live

227 Varicella-zoster virus (VZV), of the family Alphaherpesv

228 showed cytopathic changes, but HSV-1, unlike varicella-zoster virus (VZV), only rarely infected satel

229 Like varicella-zoster virus (VZV), simian varicella virus (SV

230 cilitate the generation of mutant viruses of varicella-zoster virus (VZV), the agent causing varicell

231 nation was more likely to identify wild-type varicella-zoster virus (VZV), whereas the presence of Ok

232 In varicella-zoster virus (VZV)-infected primary human brai

233 the risk of herpes zoster (HZ), we compared varicella-zoster virus (VZV)-specific and nonspecific T-

234 Varicella-zoster virus (VZV)-specific cell-mediated immu

235 n association with an age-related decline in varicella-zoster virus (VZV)-specific cell-mediated immu

236 udy were to evaluate the association between varicella-zoster virus (VZV)-specific humoral and cell-m

237 To measure varicella-zoster virus (VZV)-specific immune responses u

238 lication that can occur with reactivation of varicella-zoster virus (VZV).

239 itive GCA is associated with TA infection by varicella-zoster virus (VZV).

240 rus (CMV), herpes simplex viruses (HSV), and varicella-zoster virus (VZV).

241 rpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV).

242 ly recognized component of the life cycle of varicella-zoster virus (VZV).

243 potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

244 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesv

245 onal and pathogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

246 cropsy of two monkeys inoculated with simian varicella-zoster virus and euthanized 117 days later.

247 ia in adults includes common agents, such as varicella-zoster virus and influenza virus, as well as r

248 ate changes in the molecular epidemiology of varicella-zoster virus and the effect of immunization wi

249 Varicella-zoster virus antigen was found in 45 of 70 GCA

250 Varicella-zoster virus antigen was frequently found in p

251 e whether herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in tempor

252 gical boosting, through which reexposures to varicella-zoster virus are thought to reduce the individ

253 clonal antibodies against a major antigen of varicella-zoster virus called gE.

254 ES by the corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

255 th HSE (p.Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

256 the phenotypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role

257 rpes zoster is a common late complication of varicella-zoster virus exposure and can be further compl

258 hus, a 30-h delay after death did not affect varicella-zoster virus expression in latently infected g

259 Studies of varicella-zoster virus gene expression during latency re

260 The varicella-zoster virus geometric mean titer (GMT) and ge

261 ve (at months 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted wi

262 An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vacci

263 ubjects received 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with

264 g older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adju

265 zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with su

266 equences of wild-type and vaccine strains of varicella-zoster virus have been published and listed in

267 transfected cells, whereas expression of the varicella-zoster virus ICP22 homolog, ORF63, does not.

268 or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more we

269 erties that may favor reactivation of latent varicella-zoster virus infection.

270 While varicella-zoster virus is also insensitive to interferon

271 regulate infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, w

272 Because features of varicella-zoster virus latency are similar in primate an

273 The varicella-zoster virus major transactivator, IE62, conta

274 Available varicella-zoster virus models can be classified in 3 mai

275 -coinfected children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfec

276 lives ranging from an estimated 50 years for varicella-zoster virus to more than 200 years for other

277 ng heat-inactivated or replication-defective varicella-zoster virus to prevent HZ in immunocompromise

278 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-z

279 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in

280 HHV-1 and Varicella-Zoster virus were detected only twice and HHV-

281 ty for CMV, EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old c

282 ncing to identify nosocomial transmission of varicella-zoster virus with fatal outcome.

283 2, human herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryp

284 antigens (vaccinia, measles, mumps, rubella, varicella-zoster virus, and Epstein-Barr virus) and nonr

285 Findings from skin biopsy, viral culture for varicella-zoster virus, and skin prick test to common fo

286 (HSV) and other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navi

287 es (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyss

288 h HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uv

289 Among the 131 live births to varicella-zoster virus-seronegative women, there was no

290 in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to va

291 1, CTLA-4, and TIM-3, whereas <2% of CMV- or varicella-zoster virus-specific CD4(+) T cells expressed

292 the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA)

293 losely related to herpes simplex viruses and varicella-zoster virus.

294 G synthesis, and elevated antibody titers to varicella-zoster virus.

295 d, for example, in relation to pertussis and varicella-zoster virus.

296 ation were detected in OPV, mumps virus, and varicella-zoster virus.

297 uses herpes simplex virus type 1 (HSV-1) and varicella-zoster virus.

298 known as breakthrough disease, if exposed to varicella-zoster virus.

299 erpesviruses herpes simplex virus type 1 and varicella-zoster virus.

300 nuated varicella vaccine virus and wild-type varicella-zoster virus.